| | | |

Invasiveness of Peritoneal Mesothelioma: MRI Beats CT for Assessment

invasiveness of peritoneal mesothelioma

New research shows MRI beats CT when it comes to measuring the invasiveness of peritoneal mesothelioma.

Scientists from several of the top US cancer centers ran the study. It included nearly 500 mesothelioma patients and appears in the journal Clinical Colorectal Cancer

The study shows that the invasiveness of peritoneal mesothelioma is more visible on MRI than it is on CT. The news could make a difference in how doctors plan peritoneal mesothelioma treatment. 

Peritoneal Cancer Index and Mesothelioma

Peritoneal mesothelioma cancer grows on the peritoneal membrane lining the abdomen. Like all forms of mesothelioma, it usually comes from exposure to asbestos. Peritoneal mesothelioma accounts for about a fifth of all mesothelioma cases. 

Doctors assess the invasiveness of peritoneal mesothelioma using the Peritoneal Cancer Index (PCI). The PCI assigns a number based on how many regions of the abdomen the cancer is in. The higher the PCI, the more invasive the cancer. 

Doctors use the PCI to plan for surgery and other mesothelioma treatments. PCI can determine whether a mesothelioma patient is a candidate for CRS surgery with HIPEC.

Assessing Invasiveness of Peritoneal Mesothelioma

The only fool-proof way to determine the invasiveness of peritoneal mesothelioma is to operate. But imaging tools like MRI and CT can give doctors a pretty good idea of the PCI before surgery. 

Magnetic resonance imaging (MRI) uses a strong magnet and radio waves to create an image of the inside of the body. Computerized tomography (CT) creates an image by piecing together a series of X-ray pictures.

The new study included 488 patients with peritoneal cancer. Eight percent of the patients had peritoneal mesothelioma. All study subjects underwent CT and/or MRI prior to surgery with heated intraperitoneal chemotherapy (HIPEC).  The goal of the study was to see how closely the actual invasiveness of peritoneal mesothelioma matched the predictions based on imaging studies.

MRI Versus CT for Imaging Mesothelioma

Both MRI and CT images gave doctors a pretty good idea of each patient’s PCI. But some cancers seemed to be more visible with one type of imaging than the other. 

For patients with appendiceal or colorectal cancer, CT imaging correlated well with the PCI. But CT was not as good at showing the invasiveness of peritoneal mesothelioma. 

On the other hand, the researchers say “MRI-PCI was correlated with intraoperative-PCI for all histologies.” That includes peritoneal mesothelioma. They conclude, “MRI appears to be superior for invasive appendiceal and peritoneal mesothelioma.” A larger study will be needed to validate the idea.

The invasiveness of peritoneal mesothelioma has a bearing on surgery outcomes. The study showed that patients with a PCI above 15 tended to have less complete cytoreduction. That means doctors were not able to remove all of the cancer. 

Source:

Lee, RM, et al, “What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative”, December 12, 2019, https://www.clinical-colorectal-cancer.com/article/S1533-0028(19)30483-9/fulltext

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…